High Serum Prolactin Associated With Poor Prognosis in Carcinoma of the Prostate

Mee, A. D.; Khan, Omar A.; Mashiter, Κ.

doi:10.1016/s0022-5347(17)47334-4

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The role of prolactin in prostatic cancer is unclear. High plasma prolactin level have been reported to carry a poor prognosis [26] and the proliferation of androgen‐independent human prostate cell line can be significantly modulated by prolactin [27]. Rana et al [28] speculated that the combined maximum suppression of androgen and prolactin offers a significant improvement in response for advanced prostatic cancer.…”

Section: Discussionmentioning

confidence: 99%

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

Chen

Lin

et al. 2002

BJU International

View full text Add to dashboard Cite

Objective To evaluate whether pretreatment serum hormone levels are a prognostic factor for prostatic cancer with bony metastasis under hormonal treatment. Between 1980 and1994, 96 patients with prostate cancer and bony metastasis were included for an evaluation by a retrospective review of their charts. All 96 had received hormonal treatment after a diagnosis of metastatic prostatic carcinoma. Serum testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin were assessed before treatment. The patients were divided into two groups according to their response during the follow-up. Group 1 (good response) had no change or resolution of metastatic lesion(s) on the bone scan and a declining prostatespecific antigen (PSA) level. Group 2 had increased PSA or progression of metastatic lesion(s) on the bone scan. Tumours were graded as low (2-4), intermediate (5-7) and high (8-10) using the Gleason score. Patients and methodsResults There were 43 patients in group 1 and 53 in group 2; the overall mean (SD) age was 72.5 (6.8) years and the follow-up 29.5 (0.5) months. The respective mean (SD) levels of testosterone, LH, FSH and prolactin before treatment were 4.6 (1.6) ng/mL, 20.2 (13.3) mIU/mL, 19.6 (18.6) mIU/mL and 20.7 (12.1) ng/mL in group 1, and 2.6 (1.0) ng/mL, 27.3 (11.0) mIU/mL, 27.1 (9.8) mIU/mL and 41.3 (28.4) ng/mL in group 2. The level of testosterone was significantly higher in group 1 than in group 2, while LH, FSH and prolactin were significantly lower in group 1 than in group 2. When stratified by tumour grade, patients in group 1 still had significantly higher pretreatment testosterone and lower LH, FSH and prolactin than those in group 2. Conclusion Higher testosterone and lower LH, FSH and prolactin levels were good prognostic factors for patients with metastatic prostatic cancer under hormonal treatment, irrespective of tumour grading.

show abstract

Section: Discussionmentioning

confidence: 99%

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

Chen

Lin

et al. 2002

BJU International

View full text Add to dashboard Cite

show abstract

“…It seems unlikely that this small reduction in prolactin contributes directly to the tumour response. It is interesting to note, however, that elevated levels of prolactin may be associated with a poor prognosis (Mee et al, 1984). If this is the case, then any treatment that potentially increases the levels of prolactin should be avoided.…”

Section: Overall Responsementioning

confidence: 99%

Orchiectomy versus Long‐acting D‐Trp‐6‐LHRH in Advanced Prostatic Cancer

Parmar

Edwards

Phillips

et al. 1987

British Journal of Urology

View full text Add to dashboard Cite

One hundred and four patients were randomised for the study. Fifty-five were entered into the D-Trp-6-LHRH group and 49 into the orchiectomy group. All pre-treatment patient characteristics were similar and testosterone levels at 1 month or later were in the castrate range in both groups. Forty-six patients (83%) in the D-Trp-6-LHRH group and 40 (82%) in the orchiectomy group had a partial remission or stable disease at 3 months or later. There was no significant difference between the groups for response or survival. Three patients in the D-Trp-6-LHRH group had a disease "flare" in the first 10 days of treatment. The flare symptoms resolved by the end of 4 to 8 weeks. The incidence of flushing, decreased libido and impotence was similar in both groups. Although there was less psychological morbidity in the D-Trp-6-LHRH group the difference did not reach statistical significance. Our results indicate that long-acting D-Trp-6-LHRH offers a safe and highly effective alternative to orchiectomy.

show abstract

“…Some investigators failed to observe any difference between prostatic carcinoma patients, and normal age-matched controls [7], Others reported that prostatic-cancer pa tients secrete significantly more prolactin than agematched subjects with benign prostatic hypertrophy [8,9]. Further, increases in prolactin levels were reported among cancer patients treated with estrogen drugs [10], Mee et al [11] observed that patients with prostatic can cer with high levels of prolactin have a shorter life expec tancy. Based on the conclusion that prolactin may be involved in the progress of the disease, it was even sug gested to treat patients with carcinoma of the prostate with levodopa (L-dopa), a known inhibitor of prolactin secretion [8],…”

Section: Resultsmentioning

confidence: 99%

Serum Prolactin Levels in Patients Treated with a Gonadotropin-Releasing Hormone Analogue for Adenocarcinoma of the Prostate

Yi¹,

Korczak²,

Lindner³

1991

Eur Urol

View full text Add to dashboard Cite

High Serum Prolactin Associated With Poor Prognosis in Carcinoma of the Prostate

Cited by 5 publications

References 0 publications

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

Orchiectomy versus Long‐acting D‐Trp‐6‐LHRH in Advanced Prostatic Cancer

Serum Prolactin Levels in Patients Treated with a Gonadotropin-Releasing Hormone Analogue for Adenocarcinoma of the Prostate

Contact Info

Product

Resources

About